RU2007127859A - Двойные антитромботические ингибиторы, содержащие остаток биотина - Google Patents
Двойные антитромботические ингибиторы, содержащие остаток биотина Download PDFInfo
- Publication number
- RU2007127859A RU2007127859A RU2007127859/04A RU2007127859A RU2007127859A RU 2007127859 A RU2007127859 A RU 2007127859A RU 2007127859/04 A RU2007127859/04 A RU 2007127859/04A RU 2007127859 A RU2007127859 A RU 2007127859A RU 2007127859 A RU2007127859 A RU 2007127859A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- residue
- formula
- oligosaccharide
- biotin
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Surgery (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Claims (25)
1. Антитромботическое соединение формулы (I)
олигосахарид-спейсер-A, (I)
где олигосахарид является отрицательно заряженным олигосахаридным остатком, содержащим от двух до двадцати пяти моносахаридных остатков, заряд компенсируется положительно заряженным противоионом, и где олигосахаридный остаток получен из олигосахарида, который имеет (AT-III опосредованную) анти-Ха активность per se;
спейсер - по существу фармакологически неактивный подвижно связанный остаток, имеющий цепь длиной от 10 до 70 атомов;
А - остаток -(CH[NH-SO2-R1][CO-NR2-CH(4-бензамидин)-CO-NR3R4],
R1 - фенил, нафтил, 1,2,3,4-тетрагидронафтил, (изо)хинолинил, тетрагидро(изо)хинолинил, 3,4-дигидро-1Н-изохинолинил, хроманил или камфорная группа, где группы могут необязательно быть замещены одним или более заместителями, выбранными из (1-8С)алкила или (1-8С)алкокси; где R2 и R3 являются независимо Н или (1-8С)алкилом; R4 - (1-8С)алкил или (3-8С)циклоалкил; или R3 и R4 вместе с атомом азота, с которым они связаны, являются неароматическим 4-8-членным кольцом, необязательно содержащим другой гетероатом, кольцо необязательно может быть замещено (1-8С)алкилом или SO2-(1-8С)алкилом; или его фармацевтически приемлемая соль, пролекарство или сольват;
где соединение формулы I дополнительно содержит по крайней мере одну ковалентную связь с остатком биотина или его аналогом.
2. Соединение по п. 1, где олигосахаридный остаток содержит от двух до шестнадцати моносахаридных остатков.
3. Соединение по п. 2, где олигосахарид представляет собой сульфатированный пентасахаридный остаток.
7. Соединение по п. 1, где спейсер имеет длину 10-50 атомов, предпочтительно 16-22 и наиболее предпочтительно 19 атомов.
8. Соединение по п. 7, где спейсер имеет длину 16-22 атома.
9. Соединение по п. 1, где спейсер содержит по меньшей мере один -(СН2СН2О)-элемент.
10. Соединение по п. 1, где R1 - фенил или нафтил, необязательно замещенный одним или более заместителями, выбранными из метила или метокси.
11. Соединение по п. 10, где R1 - 4-метокси-2,3,6-триметилфенил.
12. Соединение по п. 1, где NR3R4 являются пиперидинильной группой.
13. Соединение по п. 1, где R2 - Н.
14. Соединение по п. 1, содержащее одну ковалентную связь с остатком биотина или его аналогом.
15. Соединение по п. 1, где олигосахаридный остаток соединения формулы I содержит одну ковалентную связь с остатком биотина или его аналогом.
17. Соединение по п. 1, где спейсер соединения формулы I содержит одну ковалентную связь с остатком биотина или его аналогом.
18. Соединение по п. 17, где спейсер соединения формулы I содержит одну ковалентную связь с аналогом биотина, имеющим формулу -(CH2)4-NR-BT, где R и BT описаны ранее.
20. Соединение по п. 19 в форме его натриевой соли.
21. Соединение по п. 1, где остаток А соединения формулы I содержит ковалентную связь с остатком биотина или его аналогом.
22. Фармацевтическая композиция содержит соединения по любому из пп. 1-21 и фармацевтически приемлемые вспомогательные вещества.
23. Способ получения соединения формулы I, включающий стадию, где бензамидиновый компонент - остаток А в форме предшественника является 1,2,4-оксадиазолин-5-оновой группой, превращенной в бензамидин снятием защитной группы.
24. Соединение по любому из пп. 1-21 для применения в терапии.
25. Применение соединения по любому из пп. 1-21 для изготовления лекарственного средства для лечения или предотвращения тромбоза или других тромбинсвязанных заболеваний.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04106964 | 2004-12-23 | ||
EP04106964.2 | 2004-12-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2007127859A true RU2007127859A (ru) | 2009-01-27 |
RU2403259C2 RU2403259C2 (ru) | 2010-11-10 |
Family
ID=35160114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007127859/04A RU2403259C2 (ru) | 2004-12-23 | 2005-12-21 | Двойные антитромботические ингибиторы, содержащие остаток биотина |
Country Status (29)
Country | Link |
---|---|
US (3) | US8168595B2 (ru) |
EP (1) | EP1830887B1 (ru) |
JP (2) | JP5130051B2 (ru) |
KR (1) | KR101284922B1 (ru) |
CN (1) | CN101087622A (ru) |
AR (1) | AR053657A1 (ru) |
AT (1) | ATE500846T1 (ru) |
AU (1) | AU2005318134B2 (ru) |
BR (1) | BRPI0518560A2 (ru) |
CA (1) | CA2592436C (ru) |
DE (1) | DE602005026859D1 (ru) |
DK (1) | DK1830887T3 (ru) |
ES (1) | ES2361921T3 (ru) |
HK (1) | HK1106712A1 (ru) |
HR (1) | HRP20110330T1 (ru) |
IL (2) | IL183713A (ru) |
MX (1) | MX2007007837A (ru) |
MY (1) | MY146121A (ru) |
NO (1) | NO20072878L (ru) |
NZ (1) | NZ555739A (ru) |
PE (1) | PE20060773A1 (ru) |
PL (1) | PL1830887T3 (ru) |
PT (1) | PT1830887E (ru) |
RU (1) | RU2403259C2 (ru) |
SI (1) | SI1830887T1 (ru) |
TW (1) | TWI403334B (ru) |
UA (1) | UA88793C2 (ru) |
WO (1) | WO2006067173A2 (ru) |
ZA (1) | ZA200705088B (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI403334B (zh) * | 2004-12-23 | 2013-08-01 | Merck Sharp & Dohme | 包含生物素殘基之抗血栓雙重抑制劑 |
CA2784529C (en) | 2009-12-18 | 2018-05-22 | Catalent France Beinheim Sa | Pharmaceutical oral dosage form containing a synthetic oligosaccharide |
FR2974478A1 (fr) | 2011-04-28 | 2012-11-02 | Endotis Pharma | Conjugues d'oligosaccharides en prevention des lesions d'ischemie-reperfusion |
ES2560467T3 (es) | 2011-06-17 | 2016-02-19 | Carbomimetics | Pentasacáridos sintéticos que tienen vida media corta y alta actividad |
WO2013007762A1 (en) | 2011-07-11 | 2013-01-17 | Endotis Pharma | Combination of an anticoagulant and avidin useful in surgical intervention and clinical procedure |
US10660973B2 (en) | 2015-04-28 | 2020-05-26 | Duke University | Thrombus imaging aptamers and methods of using same |
CN109982707A (zh) | 2016-09-16 | 2019-07-05 | 杜克大学 | 血管性血友病因子(vwf)靶向剂及其使用方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4252951A (en) * | 1979-10-09 | 1981-02-24 | Eli Lilly And Company | Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid |
EP0454220B1 (en) | 1990-04-23 | 1993-08-18 | Akzo Nobel N.V. | Carbohydrate derivatives comprising a trisaccharide unit |
IL102758A (en) | 1991-08-23 | 1997-03-18 | Akzo Nv | Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them |
ES2147216T3 (es) | 1993-09-01 | 2000-09-01 | Akzo Nobel Nv | Bisconjugados que comprenden dos sacaridos y un grupo de union. |
FR2749849B1 (fr) * | 1996-06-14 | 1998-09-04 | Sanofi Sa | Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant |
FR2751334B1 (fr) * | 1996-07-19 | 1998-10-16 | Sanofi Sa | Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant |
FR2773804B1 (fr) * | 1998-01-19 | 2000-02-18 | Sanofi Sa | Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant |
FR2773801B1 (fr) * | 1998-01-19 | 2000-05-12 | Sanofi Sa | Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant |
BR9911300A (pt) * | 1998-06-17 | 2001-04-03 | Akzo Nobel Nv | Composto, composição farmacêutica, e, uso do composto |
TWI289566B (en) * | 1999-12-07 | 2007-11-11 | N.V.Organon | Antithrombotic compound |
FR2814463B1 (fr) * | 2000-09-22 | 2002-11-15 | Sanofi Synthelabo | Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine |
TWI403334B (zh) * | 2004-12-23 | 2013-08-01 | Merck Sharp & Dohme | 包含生物素殘基之抗血栓雙重抑制劑 |
ES2362011T3 (es) * | 2005-10-10 | 2011-06-27 | N.V. Organon | Inhibidores duales antitrombóticos anticoagulantes que comprenden una marca de biotina. |
-
2005
- 2005-12-14 TW TW094144361A patent/TWI403334B/zh not_active IP Right Cessation
- 2005-12-16 PE PE2005001503A patent/PE20060773A1/es not_active Application Discontinuation
- 2005-12-20 MY MYPI20056026A patent/MY146121A/en unknown
- 2005-12-21 CN CNA2005800444919A patent/CN101087622A/zh active Pending
- 2005-12-21 WO PCT/EP2005/057011 patent/WO2006067173A2/en active Application Filing
- 2005-12-21 MX MX2007007837A patent/MX2007007837A/es active IP Right Grant
- 2005-12-21 PL PL05821769T patent/PL1830887T3/pl unknown
- 2005-12-21 UA UAA200706654A patent/UA88793C2/ru unknown
- 2005-12-21 BR BRPI0518560-2A patent/BRPI0518560A2/pt not_active IP Right Cessation
- 2005-12-21 ES ES05821769T patent/ES2361921T3/es active Active
- 2005-12-21 KR KR1020077017005A patent/KR101284922B1/ko not_active IP Right Cessation
- 2005-12-21 AU AU2005318134A patent/AU2005318134B2/en active Active
- 2005-12-21 DK DK05821769.6T patent/DK1830887T3/da active
- 2005-12-21 DE DE602005026859T patent/DE602005026859D1/de active Active
- 2005-12-21 NZ NZ555739A patent/NZ555739A/en not_active IP Right Cessation
- 2005-12-21 CA CA2592436A patent/CA2592436C/en active Active
- 2005-12-21 SI SI200531279T patent/SI1830887T1/sl unknown
- 2005-12-21 PT PT05821769T patent/PT1830887E/pt unknown
- 2005-12-21 RU RU2007127859/04A patent/RU2403259C2/ru not_active IP Right Cessation
- 2005-12-21 AT AT05821769T patent/ATE500846T1/de active
- 2005-12-21 EP EP05821769A patent/EP1830887B1/en active Active
- 2005-12-21 JP JP2007547509A patent/JP5130051B2/ja active Active
- 2005-12-21 US US11/722,444 patent/US8168595B2/en active Active
- 2005-12-22 AR ARP050105472A patent/AR053657A1/es not_active Application Discontinuation
-
2007
- 2007-06-06 NO NO20072878A patent/NO20072878L/no not_active Application Discontinuation
- 2007-06-06 IL IL183713A patent/IL183713A/en not_active IP Right Cessation
- 2007-06-13 ZA ZA200705088A patent/ZA200705088B/xx unknown
-
2008
- 2008-01-10 HK HK08100324.9A patent/HK1106712A1/xx not_active IP Right Cessation
-
2011
- 2011-05-06 HR HR20110330T patent/HRP20110330T1/hr unknown
- 2011-12-18 IL IL217047A patent/IL217047A0/en unknown
-
2012
- 2012-04-04 US US13/438,905 patent/US8445450B2/en active Active
- 2012-04-04 US US13/439,012 patent/US20120238512A1/en not_active Abandoned
- 2012-09-14 JP JP2012202307A patent/JP5632886B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007127859A (ru) | Двойные антитромботические ингибиторы, содержащие остаток биотина | |
KR101166927B1 (ko) | 골수증식 질환의 치료 및 관리를 위한 면역조절 화합물의사용 방법 및 이를 포함하는 조성물 | |
KR100822149B1 (ko) | 암 및 기타 질병의 치료 및 관리를 위해 면역 조절화합물을 이용하는 방법 및 조성물 | |
KR101483802B1 (ko) | 외투층 세포 림프종의 치료에 있어서 3-(4-아미노-1-옥소-1,3-디히드로-이소인돌-2-일)-피페리딘-2,6-디온의 용도 | |
JP2007534632A (ja) | アスベスト関連疾患および障害の治療および管理のための免疫調節化合物の使用方法およびそれを含む組成物 | |
KR20050072801A (ko) | 암 및 기타 질환의 치료 및 관리를 위한 면역조절 화합물의사용 방법 및 이를 사용하는 조성물 | |
EA026100B1 (ru) | Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение | |
KR100923173B1 (ko) | 암 및 다른 질환의 치료 및 관리를 위한 선택적 시토킨억제 약물의 사용 방법 및 그 조성물 | |
CA2997671A1 (en) | Combination therapies for treating cancer | |
JP2012525437A5 (ru) | ||
RU2001101556A (ru) | Антитромботические соединения | |
CA2334863A1 (en) | Antithrombotic compounds | |
JP2009511543A5 (ru) | ||
RU2008118365A (ru) | Антитромботические двойные ингибиторы, включающие биотиновую метку | |
KR900017577A (ko) | 폴리아민 유도체를 사용하여 세포- 중재의 면역성을 상승시키는 방법 | |
AU2003226361B2 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases | |
AU2004288713A1 (en) | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders | |
JP2007536223A (ja) | 骨髄増殖性疾患の治療及び管理のための免疫調節化合物を含む組成物、及びその使用方法 | |
RU2005128829A (ru) | Обладающие противоопухолевым действием 2-замещенные 18а-гомоэстра-1, 3, 5( 10 )-триен-3-илсульфаматы | |
JP2007536221A (ja) | 骨髄増殖性疾患を治療及び管理するための選択的サイトカイン阻害薬の使用方法及びそれを含む組成物 | |
AR051319A1 (es) | Administracion pulmonar de un compuesto antitrombotico | |
KR20070007203A (ko) | 골수증식성 질환의 치료 및 관리를 위해 선택적 사이토킨억제성 약물을 사용하는 방법 및 그를 포함하는 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC43 | Official registration of the transfer of the exclusive right without contract for inventions |
Effective date: 20120326 |
|
PC43 | Official registration of the transfer of the exclusive right without contract for inventions |
Effective date: 20130917 |
|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20131222 |